Beam Therapeutics Inc. reported a net loss of $79.99 million for the year ended December 31, 2025, a significant decrease from the $376.74 million net loss reported for the year ended December 31, 2024. The company's revenue increased to $139.74 million in 2025, compared to $63.52 million in 2024. Research and development expenses also increased, totaling $409.62 million in 2025 compared to $367.56 million in the previous year, driven by increased clinical and manufacturing activities, employee-related expenses, and a one-time in-process research and development charge.
The company's financial performance in 2025 was significantly influenced by strategic developments, including the completion of a collaboration deal with Pfizer, which contributed to the increase in revenue. Additionally, Beam Therapeutics recognized a gain of $255.15 million from the sale of its equity method investment in Orbital Therapeutics following its acquisition by Bristol-Myers Squibb Company. General and administrative expenses saw a slight increase, reaching $113.82 million in 2025 from $111.53 million in 2024, primarily due to higher personnel and legal costs.
Key operational developments for Beam Therapeutics include the continued advancement of its lead programs, particularly risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency (AATD). The company presented updated positive data from its Phase 1/2 clinical trial of risto-cel, with plans to submit a biologics license application (BLA) as early as year-end 2026. Beam also reached alignment with the FDA on a potential accelerated approval pathway for BEAM-302, with plans to enroll approximately 50 additional patients in an expansion of the ongoing Phase 1/2 clinical trial.
Looking ahead, Beam Therapeutics anticipates that its existing cash, cash equivalents, and marketable securities, totaling $1.2 billion as of December 31, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months. The company expects its operating expenses to increase as it continues to advance its clinical programs, expand its manufacturing capabilities, and pursue new research and development opportunities. Beam Therapeutics also entered into a financing agreement for a senior secured term loan facility of up to $500 million, providing additional financial flexibility.
About Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company specializing in precision genetic medicines through proprietary base editing technology, which enables precise, efficient single-base genome modifications without double-stranded DNA breaks. Its platform integrates gene editing, delivery modalities, and manufacturing to develop therapies for genetic and hematological diseases, targeting markets with high unmet medical needs. Beam’s business model combines internal development with strategic collaborations to advance and commercialize innovative gene editing treatments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.